175 related articles for article (PubMed ID: 38607318)
21. Target protein localization and its impact on PROTAC-mediated degradation.
Simpson LM; Glennie L; Brewer A; Zhao JF; Crooks J; Shpiro N; Sapkota GP
Cell Chem Biol; 2022 Oct; 29(10):1482-1504.e7. PubMed ID: 36075213
[TBL] [Abstract][Full Text] [Related]
22. Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos.
Meng F; Xu C; Park KS; Kaniskan HÜ; Wang GG; Jin J
J Med Chem; 2022 Aug; 65(15):10611-10625. PubMed ID: 35895319
[TBL] [Abstract][Full Text] [Related]
23. Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.
Hu J; Wei J; Yim H; Wang L; Xie L; Jin MS; Kabir M; Qin L; Chen X; Liu J; Jin J
J Med Chem; 2020 Dec; 63(24):15883-15905. PubMed ID: 33284613
[TBL] [Abstract][Full Text] [Related]
24. Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins.
Shirasaki R; Matthews GM; Gandolfi S; de Matos Simoes R; Buckley DL; Raja Vora J; Sievers QL; Brüggenthies JB; Dashevsky O; Poarch H; Tang H; Bariteau MA; Sheffer M; Hu Y; Downey-Kopyscinski SL; Hengeveld PJ; Glassner BJ; Dhimolea E; Ott CJ; Zhang T; Kwiatkowski NP; Laubach JP; Schlossman RL; Richardson PG; Culhane AC; Groen RWJ; Fischer ES; Vazquez F; Tsherniak A; Hahn WC; Levy J; Auclair D; Licht JD; Keats JJ; Boise LH; Ebert BL; Bradner JE; Gray NS; Mitsiades CS
Cell Rep; 2021 Jan; 34(1):108532. PubMed ID: 33406420
[TBL] [Abstract][Full Text] [Related]
25. Discovery of E3 Ligase Ligands for Target Protein Degradation.
Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
[TBL] [Abstract][Full Text] [Related]
26. Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic.
Li D; Yu X; Kottur J; Gong W; Zhang Z; Storey AJ; Tsai YH; Uryu H; Shen Y; Byrum SD; Edmondson RD; Mackintosh SG; Cai L; Liu Z; Aggarwal AK; Tackett AJ; Liu J; Jin J; Wang GG
Oncogene; 2022 Jun; 41(24):3328-3340. PubMed ID: 35525905
[TBL] [Abstract][Full Text] [Related]
27. Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases.
Aublette MC; Harrison TA; Thorpe EJ; Gadd MS
Bioorg Med Chem Lett; 2022 May; 64():128636. PubMed ID: 35231578
[TBL] [Abstract][Full Text] [Related]
28. Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras.
Takwale AD; Jo SH; Jeon YU; Kim HS; Shin CH; Lee HK; Ahn S; Lee CO; Du Ha J; Kim JH; Hwang JY
Eur J Med Chem; 2020 Dec; 208():112769. PubMed ID: 32961381
[TBL] [Abstract][Full Text] [Related]
29. Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies.
Yu X; Xu J; Shen Y; Cahuzac KM; Park KS; Dale B; Liu J; Parsons RE; Jin J
J Med Chem; 2022 Feb; 65(4):3644-3666. PubMed ID: 35119851
[TBL] [Abstract][Full Text] [Related]
30. Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2.
Liu Z; Hu X; Wang Q; Wu X; Zhang Q; Wei W; Su X; He H; Zhou S; Hu R; Ye T; Zhu Y; Wang N; Yu L
J Med Chem; 2021 Mar; 64(5):2829-2848. PubMed ID: 33606537
[TBL] [Abstract][Full Text] [Related]
31. Protein degraders - from thalidomide to new PROTACs.
Ito T
J Biochem; 2024 Apr; 175(5):507-519. PubMed ID: 38140952
[TBL] [Abstract][Full Text] [Related]
32. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
[TBL] [Abstract][Full Text] [Related]
33. Cereblon target validation using a covalent inhibitor of neosubstrate recruitment.
Dann GP; Liu H; Nowak RP; Jones LH
Methods Enzymol; 2023; 681():155-167. PubMed ID: 36764755
[TBL] [Abstract][Full Text] [Related]
34. Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation.
Xie H; Li C; Tang H; Tandon I; Liao J; Roberts BL; Zhao Y; Tang W
J Med Chem; 2023 Feb; 66(4):2904-2917. PubMed ID: 36749666
[TBL] [Abstract][Full Text] [Related]
35. Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs.
Steinebach C; Bricelj A; Murgai A; Sosič I; Bischof L; Ng YLD; Heim C; Maiwald S; Proj M; Voget R; Feller F; Košmrlj J; Sapozhnikova V; Schmidt A; Zuleeg MR; Lemnitzer P; Mertins P; Hansen FK; Gütschow M; Krönke J; Hartmann MD
J Med Chem; 2023 Nov; 66(21):14513-14543. PubMed ID: 37902300
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines.
Krasavin M; Adamchik M; Bubyrev A; Heim C; Maiwald S; Zhukovsky D; Zhmurov P; Bunev A; Hartmann MD
Eur J Med Chem; 2023 Jan; 246():114990. PubMed ID: 36476642
[TBL] [Abstract][Full Text] [Related]
37. Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase.
Degorce SL; Tavana O; Banks E; Crafter C; Gingipalli L; Kouvchinov D; Mao Y; Pachl F; Solanki A; Valge-Archer V; Yang B; Edmondson SD
J Med Chem; 2020 Sep; 63(18):10460-10473. PubMed ID: 32803978
[TBL] [Abstract][Full Text] [Related]
38. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.
Yang K; Zhao Y; Nie X; Wu H; Wang B; Almodovar-Rivera CM; Xie H; Tang W
Cell Chem Biol; 2020 Jul; 27(7):866-876.e8. PubMed ID: 32413286
[TBL] [Abstract][Full Text] [Related]
39. Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library.
Powell CE; Du G; Che J; He Z; Donovan KA; Yue H; Wang ES; Nowak RP; Zhang T; Fischer ES; Gray NS
ACS Chem Biol; 2020 Oct; 15(10):2722-2730. PubMed ID: 32865967
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity.
Desantis J; Bazzacco A; Eleuteri M; Tuci S; Bianconi E; Macchiarulo A; Mercorelli B; Loregian A; Goracci L
Eur J Med Chem; 2024 Mar; 268():116202. PubMed ID: 38394929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
